Literature DB >> 9398043

Increased presence of CD34+ cells in the peripheral blood of head and neck cancer patients and their differentiation into dendritic cells.

T Garrity1, R Pandit, M A Wright, J Benefield, S Keni, M R Young.   

Abstract

Patients with head and neck squamous cell carcinoma (HNSCC) have profound immune deficiencies. In 65% of these patients, there is an increased intra-tumoral presence of immune-suppressive CD34+ progenitor cells. The goal of the present study was to determine whether CD34+ cell levels were also increased in the peripheral blood of HNSCC patients and if these immune-suppressive cells could be differentiated into dendritic cells. Our results showed that CD34+ cell levels are increased in the peripheral blood of HNSCC patients. To assess if these CD34+ cells could differentiate into dendritic cells, they were isolated from the blood of HNSCC patients and cultured for 12 days with various cytokine combinations. Culturing CD34+ cells with stem cell factor (c-kit ligand) plus granulocyte-macrophage colony-stimulating factor resulted in the appearance of a significant proportion of cells expressing phenotypic markers characteristic of dendritic cells. Also, including tumor necrosis factor-alpha yielded a significant proportion of cells resembling the bipotential precursor cells for dendritic cells and monocytes (CD14+CD1a+), in addition to the dendritic-like cells. When the differentiation inducer 1alpha,25-dihydroxyvitamin D3 [1,25(OH)2D3] was added along with the cytokine combinations, the yield of cells having characteristics of dendritic cells was further increased. Cells that were derived from CD34+ cell cultures containing 1,25(OH)2D3 had a more potent capacity to present the recall antigen tetanus toxoid to autologous peripheral blood leukocytes and to stimulate a mixed leukocyte response compared to cultures to which 1,25(OH)2D3 had not been added. Our results show that CD34+ cells, whose frequency is increased in HNSCC patients, can be differentiated into cells that phenotypically and functionally resemble dendritic cells and that 1,25(OH)2D3 accentuates this differentiation.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9398043     DOI: 10.1002/(sici)1097-0215(19971127)73:5<663::aid-ijc9>3.0.co;2-v

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  36 in total

Review 1.  Immune Evasion by Head and Neck Cancer: Foundations for Combination Therapy.

Authors:  Joshua D Horton; Hannah M Knochelmann; Terry A Day; Chrystal M Paulos; David M Neskey
Journal:  Trends Cancer       Date:  2019-03-20

Review 2.  Immunotherapy for head and neck cancer: advances and deficiencies.

Authors:  Anna-Maria De Costa; M Rita I Young
Journal:  Anticancer Drugs       Date:  2011-08       Impact factor: 2.248

3.  Improved correlation of histological data with DCE MRI parameter maps by 3D reconstruction, reslicing and parameterization of the histological images.

Authors:  Fabian Kiessling; Martin Le-Huu; Tobias Kunert; Matthias Thorn; Silvia Vosseler; Kerstin Schmidt; Johannes Hoffend; Hans-Peter Meinzer; Norbert E Fusenig; Wolfhard Semmler
Journal:  Eur Radiol       Date:  2005-03-04       Impact factor: 5.315

4.  Failure of tumor-reactive lymph node cells to kill tumor in the presence of immune-suppressive CD34+ cells can be overcome with vitamin D3 treatment to diminish CD34+ cell levels.

Authors:  K Wiers; M A Wright; K Vellody; M R Young
Journal:  Clin Exp Metastasis       Date:  1998-04       Impact factor: 5.150

5.  Use of alpha,25-dihydroxyvitamin D3 treatment to stimulate immune infiltration into head and neck squamous cell carcinoma.

Authors:  Jarrett E Walsh; Anna-Maria Clark; Terry A Day; M Boyd Gillespie; M Rita I Young
Journal:  Hum Immunol       Date:  2010-05-16       Impact factor: 2.850

6.  Tolerance and immune suppression in the tumor microenvironment.

Authors:  Suzanne Ostrand-Rosenberg
Journal:  Cell Immunol       Date:  2015-09-30       Impact factor: 4.868

7.  Immunological modulation by 1α,25-dihydroxyvitamin D3 in patients with squamous cell carcinoma of the head and neck.

Authors:  David D Walker; Travis D Reeves; Anna-Maria de Costa; Corinne Schuyler; M Rita I Young
Journal:  Cytokine       Date:  2012-03-24       Impact factor: 3.861

Review 8.  Dendritic cell recovery post-lymphodepletion: a potential mechanism for anti-cancer adoptive T cell therapy and vaccination.

Authors:  Mohamed Labib Salem; David J Cole
Journal:  Cancer Immunol Immunother       Date:  2009-11-18       Impact factor: 6.968

Review 9.  Myeloid-Derived Suppressor Cells: Critical Cells Driving Immune Suppression in the Tumor Microenvironment.

Authors:  Katherine H Parker; Daniel W Beury; Suzanne Ostrand-Rosenberg
Journal:  Adv Cancer Res       Date:  2015-05-12       Impact factor: 6.242

10.  GM-CSF is one of the main breast tumor-derived soluble factors involved in the differentiation of CD11b-Gr1- bone marrow progenitor cells into myeloid-derived suppressor cells.

Authors:  Johanna K Morales; Maciej Kmieciak; Keith L Knutson; Harry D Bear; Masoud H Manjili
Journal:  Breast Cancer Res Treat       Date:  2009-11-08       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.